The Experts below are selected from a list of 1533 Experts worldwide ranked by ideXlab platform
Jan Menne - One of the best experts on this subject based on the ideXlab platform.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
Jens Jordan - One of the best experts on this subject based on the ideXlab platform.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
Ingrid Scheffers - One of the best experts on this subject based on the ideXlab platform.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
William H Maisel - One of the best experts on this subject based on the ideXlab platform.
-
2008 IEEE Symposium on Security and Privacy Pacemakers and Implantable Cardiac Defibrillators: Software Radio Attacks and Zero-Power Defenses
2014Co-Authors: Daniel Halperin, Benjamin Ransford, Shane S Clark, W Morgan, Tadayoshi Kohno, Thomas S. Heydt-benjamin, William H MaiselAbstract:Abstract—Our study analyzes the security and privacy properties of an implantable cardioverter defibrillator (ICD). Introduced to the U.S. market in 2003, this model of ICD includes pacemaker technology and is designed to communicate wirelessly with a nearby External Programmer in the 175 kHz frequency range. After partially reverse-engineering the ICD’s communications protocol with an oscilloscope and a software radio, we implemented several software radio-based attacks that could compromise patient safety and patient privacy. Motivated by our desire to improve patient safety, and mindful of conventional trade-offs between security and power consumption for resourceconstrained devices, we introduce three new zero-power defenses based on RF power harvesting. Two of these defenses are humancentric, bringing patients into the loop with respect to the security and privacy of their implantable medical devices (IMDs). Our contributions provide a scientific baseline for understanding the potential security and privacy risks of current and future IMDs, and introduce human-perceptible and zero-power mitigation techniques that address those risks. To the best of our knowledge, this paper is the first in our community to use general-purpose software radios to analyze and attack previously unknown radio communications protocols. I
-
pacemakers and implantable cardiac defibrillators software radio attacks and zero power defenses
IEEE Symposium on Security and Privacy, 2008Co-Authors: Daniel Halperin, Thomas S Heydtbenjamin, Benjamin Ransford, Shane S Clark, Benessa Defend, W Morgan, Tadayoshi Kohno, William H MaiselAbstract:Our study analyzes the security and privacy properties of an implantable cardioverter defibrillator (ICD). Introduced to the U.S. market in 2003, this model of ICD includes pacemaker technology and is designed to communicate wirelessly with a nearby External Programmer in the 175 kHz frequency range. After partially reverse-engineering the ICD's communications protocol with an oscilloscope and a software radio, we implemented several software radio-based attacks that could compromise patient safety and patient privacy. Motivated by our desire to improve patient safety, and mindful of conventional trade-offs between security and power consumption for resource-constrained devices, we introduce three new zero-power defenses based on RF power harvesting. Two of these defenses are human-centric, bringing patients into the loop with respect to the security and privacy of their implantable medical devices (IMDs). Our contributions provide a scientific baseline for understanding the potential security and privacy risks of current and future IMDs, and introduce human-perceptible and zero-power mitigation techniques that address those risks. To the best of our knowledge, this paper is the first in our community to use general-purpose software radios to analyze and attack previously unknown radio communications protocols.
Jan H M Tordoir - One of the best experts on this subject based on the ideXlab platform.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
-
novel baroreflex activation therapy in resistant hypertension results of a european multi center feasibility study
Journal of the American College of Cardiology, 2010Co-Authors: Ingrid Scheffers, Abraham A Kroon, Juerg Schmidli, Jens Jordan, Jan H M Tordoir, Markus G Mohaupt, Friedrich C Luft, Hermann Haller, Jan MenneAbstract:OBJECTIVES: This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. BACKGROUND: Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. METHODS: Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An External Programmer was used to optimize and individualize efficacy. RESULTS: Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. CONCLUSIONS: The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial.
